STOCK TITAN

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its third quarter 2022 investor update conference call on November 3, 2022, at 8:30 a.m. ET. Participants can join by calling (888) 330-2384 for U.S. and Canada or (240) 789-2701 internationally, using conference ID 4671230. A replay will be available starting the same day at 11:30 a.m. ET until November 17, 2022. The archived webcast will be accessible on Ironwood’s website for 14 days post-call. Ironwood focuses on advancing gastroenterological treatments, especially for IBS-C and CIC.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting Thursday, November 3, 2022 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 17, 2022. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com



Matt Roache, 617-621-8395

mroache@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

What is the date and time for Ironwood Pharmaceuticals' Q3 2022 investor update conference call?

Ironwood Pharmaceuticals will host its Q3 2022 investor update conference call on November 3, 2022, at 8:30 a.m. ET.

How can I access the Ironwood Pharmaceuticals Q3 2022 conference call?

You can access the Ironwood Pharmaceuticals Q3 2022 conference call by dialing (888) 330-2384 for the U.S. and Canada or (240) 789-2701 internationally, using the conference ID 4671230.

When will the replay of the Ironwood Pharmaceuticals conference call be available?

The replay of the Ironwood Pharmaceuticals conference call will be available starting on November 3, 2022, at 11:30 a.m. ET, until November 17, 2022.

Where can I find the archived webcast of Ironwood Pharmaceuticals' conference call?

The archived webcast of Ironwood Pharmaceuticals' conference call will be available on their website for 14 days after the call.

What is Ironwood Pharmaceuticals known for?

Ironwood Pharmaceuticals is known for its focus on gastrointestinal healthcare and the development of LINZESS, a leading treatment for IBS-C and CIC.

Ironwood Pharmaceuticals, Inc. -

NASDAQ:IRWD

IRWD Rankings

IRWD Latest News

IRWD Stock Data

718.11M
157.19M
1.68%
105.28%
5.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON